Rani Therapeutics Holdings, Inc. (RANI)

NASDAQ: RANI · IEX Real-Time Price · USD
20.67 1.11 (5.67%)
Jan 14, 2022 4:00 PM EST - Market closed
Market Cap407.44M
Revenue (ttm)3.04M
Net Income (ttm)-45.54M
Shares Out19.71M
EPS (ttm)-1.01
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume80,306
Open19.49
Previous Close19.56
Day's Range19.35 - 21.37
52-Week Range9.24 - 36.27
Betan/a
AnalystsStrong Buy
Price Target28.40 (+37.4%)
Earnings Daten/a

About RANI

Rani Therapeutics is a clinical stage biotherapeutics company advancing technologies to enable the development of orally administered biologics. We have developed the RaniPill capsule, which is our novel, proprietary and patented platform technology, intended to replace subcutaneous or IV injection of biologics with oral dosing. The RaniPill capsule is an orally ingestible pill approximately the size of a “000” capsule (or similar to the size of a standard fish oil or calcium pill) that is designed to automatically administer a precise ther...

IndustryBiotechnology
IPO DateJul 30, 2021
CEOTalat Imran
Employees91
Stock ExchangeNASDAQ
Ticker SymbolRANI
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 5 analysts, the average rating for RANI stock is "Strong Buy." The 12-month stock price forecast is 28.40, which is an increase of 37.40% from the latest price.

Price Target
$28.40
(37.40% upside)
Analyst Consensus: Strong Buy

News

Rani Therapeutics Reports Third Quarter 2021 Financial Results, Provides Corporate Update

SAN JOSE, Calif., Nov. 15, 2021 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical stage biotherapeutics company focused on the oral delivery...

2 months ago - GlobeNewsWire

Rani Therapeutics Appoints Lyn Baranowski to Board of Directors

SAN JOSE, Calif., Nov. 12, 2021 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical stage biotherapeutics company focused on advancing technol...

2 months ago - GlobeNewsWire

This Recent Biologics IPO Could Be Heading Toward a Gain of 60% or More

A game-changing pill from Rani Therapeutics may offer an easier alternative to fight debilitating diseases.

3 months ago - The Motley Fool

Rani Therapeutics to Present at Cantor Fitzgerald Virtual Global Healthcare Conference

SAN JOSE, Calif., Sept. 23, 2021 (GLOBE NEWSWIRE) -- Rani Therapeutics (Nasdaq: RANI), a clinical stage biotherapeutics company focused on the oral delivery of biologics, today announced that the compan...

3 months ago - GlobeNewsWire

Rani Therapeutics Reports Second Quarter 2021 Financial Results, Provides Corporate Update

- IPO in July 2021 raised $84.3 million in gross proceeds - - Talat Imran Appointed Chief Executive Officer - - Enhanced leadership team with key management and board of directors' appointments -

4 months ago - GlobeNewsWire

Rani Therapeutics, RxSight: 2 Bullish Health Care Stock Picks From BofA

Rani Therapeutics Holdings, Inc. (NASDAQ:RANI), an early stage platform technology company that promotes oral dosing with its RaniPill, and RxSight, Inc. (NASDAQ:RXST), an ophthalmology-focused MedTech ...

Other symbols:RXST
4 months ago - Benzinga

Rani Therapeutics Announces Closing of its Initial Public Offering and Full Exercise of Underwriters' Option to Purch...

SAN JOSE, Calif., Aug. 13, 2021 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (Nasdaq:RANI) (“Rani Therapeutics” or “Rani”), a clinical stage biotherapeutics company focused on advancing technolo...

5 months ago - GlobeNewsWire

Rani Therapeutics' $73M IPO will fund upcoming clinical trials

Rani Therapeutics, a San Jose-based company developing a pill to replace medical injections, went public on Friday.  According to S-1 filings, shares were estimated to price between $14 and $16 last week.

5 months ago - TechCrunch

Rani Therapeutics Debuts On The Nasdaq: What You Should Know About The Biopharma

Rani Therapeutics Holdings, Inc. (NASDAQ: RANI), a San Jose, California-based early stage biopharma, debuted Friday on the Nasdaq in its initial public offering. Rani Shares Trade Around IPO Price: Rani...

5 months ago - Benzinga

Rani Therapeutics Announces Pricing of Initial Public Offering

SAN JOSE, Calif., July 30, 2021 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”), a clinical stage biotherapeutics company focused on advancing technologies to enable...

5 months ago - GlobeNewsWire